4.3 Review

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

Journal

ENDOCRINOLOGY AND METABOLISM
Volume 38, Issue 1, Pages 25-33

Publisher

KOREAN ENDOCRINE SOC
DOI: 10.3803/EnM.2022.1642

Keywords

Glucagon-like peptide 1; Diabetes mellitus; type 2; Renal insufficiency; chronic

Ask authors/readers for more resources

The therapeutic benefits of GLP1 for people with type 2 diabetes and/or obesity are well-established. They should replace traditional treatment options and have potential for treating other conditions such as fatty liver disease and Alzheimer's disease.
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer's disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available